(PRWEB) January 26, 2009
SANCUSO delivers granisetron, its active component and an established preventer of nausea and vomiting, through a thin layer of adhesive that attaches the patch to the patient's skin on the outside part of the upper outer arm. The medicine is then released slowly and continuously into the bloodstream for up to 5 consecutive days of chemotherapy.
At sancuso.com you can:
- Learn the causes of nausea and vomiting as a result of chemotherapy (CINV), the different types, and how to best manage CINV
- Discover more about how the SANCUSO patch works
- Hear from other patients and caregivers who have used the SANCUSO patch
SANCUSO Recognized by TIME Magazine
SANCUSO was recently named one of the Top 10 Medical Breakthroughs of 2008 by TIME magazine.
"Being distinguished as a medical breakthrough among blood tests, gene screens and vaccines further demonstrates how important SANCUSO is to the oncology community," said Dr. Rolando Gutierrez, Chief Medical Officer US ProStrakan, Inc. "We are an organization dedicated to meeting the unmet needs of patients, and we are pleased that SANCUSO has been recognized as a product that can have such an important impact on the quality of life of people living with cancer." SANCUSO was approved by the US Food and Drug Administration (FDA) in September 2008.
For more information on SANCUSO, visit http://www.sancuso.com.
To view the complete TIME article from December 22, 2008, visit the TIME website.
Important Safety Information
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.(1) Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.(1) Mild application site reactions have occurred; remove patch if severe reaction or a generalized skin reaction occurs.(1) Avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.(1)
The most common adverse reaction is constipation (5.4%).(1) SANCUSO contains granisetron.(1) Healthcare professionals should avoid prescribing any additional products that contain granisetron.
ProStrakan Group plc is one of Europe's fastest growing pharmaceutical companies, with new US headquarters in Bedminster, New Jersey. ProStrakan is committed to developing innovative therapies to improve the lives of patients. Current products range from cancer, women's health, men's health, anesthesiology, and cardiovascular disease. For more information on ProStrakan, please visit http://www.prostrakan-usa.com.
1. SANCUSO (package insert). Bedminister, NJ: ProStrakan, Inc; 2008.
** Dec 22, 2008 Issue